DDX53 and lung cancer: Given the heterogeneity of human lung cancers, researchers have tried to include more autoantibodies (AABs) to achieve higher sensitivity with a study that used 7 AABs (p53, c-myc, HER2, NY-ESO-1, CAGE, MUC1, and GBU4-5) in European patients with lung cancer (n D 104), a sensitivity of 76% and specificity of 92% were observed [13]; and an audit study of EarlyCDT(R)-Lung (6-AABs or 7-AABs) in 1600 patients also showed high specificity of 83% or 91% [14].